ACXP insider transaction filings
Acurx Pharmaceuticals, Inc. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-04-22. Screen ACXP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ACXP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Acurx Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-22 | 4 | Sailer Carl — Director | Grant/award (A): 2,150 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Donohue James J. — Director | Grant/award (A): 2,150 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Shawah Robert G. — Chief Financial Officer | Grant/award (A): 25,900 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | DEAN JACK H — Director | Grant/award (A): 2,150 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Scodari Joseph C — Director | Grant/award (A): 2,150 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | LUCI DAVID P — President and CEO, Director | Grant/award (A): 37,100 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | HARRISON THOMAS L — Director | Grant/award (A): 2,150 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | DELUCCIA ROBERT J — Director | Grant/award (A): 37,100 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Shawah Robert G. — Chief Financial Officer | Grant/award (A): 145,500 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | LUCI DAVID P — President and CEO, Director, 10% owner | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | DELUCCIA ROBERT J — Director, 10% owner | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Sailer Carl — Director | Purchase (P): 24,631 @ $1.01 · Purchase (P): 24,631 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Donohue James J. — Director | Purchase (P): 9,852 @ $1.01 · Purchase (P): 9,852 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | DEAN JACK H — Director | Purchase (P): 9,852 @ $1.01 · Purchase (P): 9,852 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Scodari Joseph C — Director | Purchase (P): 24,631 @ $1.01 · Purchase (P): 24,631 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | LUCI DAVID P — President and CEO, Director, 10% owner | Purchase (P): 49,261 @ $1.01 · Purchase (P): 49,261 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | DELUCCIA ROBERT J — Director, 10% owner | Purchase (P): 49,261 @ $1.01 · Purchase (P): 49,261 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Sailer Carl — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Donohue James J. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | DEAN JACK H — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Scodari Joseph C — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | HARRISON THOMAS L — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Shawah Robert G. — Chief Financial Officer | Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | LUCI DAVID P — President and CEO, Director, 10% owner | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | DELUCCIA ROBERT J — Director, 10% owner | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Sailer Carl — Director | Option exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | LUCI DAVID P — President and CEO, Director, 10% owner | Option exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | DELUCCIA ROBERT J — Director, 10% owner | Gift (G): 40,000 @ $0 · Gift (G): 40,000 @ $0 · Gift (G): 30,000 @ $0 · Option exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0 | EDGAR |
Recent 8-K events — Acurx Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-04-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-22 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-19 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-07-31 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-06-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACXP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →